Kali Therapeutics has been recognized in the 2026 Endpoints 11, showcasing its innovative therapies targeting autoimmune diseases. With two clinical candidates and a partnership with Sanofi, the future looks bright.

Sanofi partners with Kali Therapeutics in TCE deal worth $180M upfront plus $1B in milestones, centered on KT501 for rheumatoid arthritis. CEO Weihao Xu leads development.

Kali Therapeutics has received clearance from the FDA for their KT501 drug, a tri-specific T-cell engager for treating autoimmune diseases. This groundbreaking step follows promising data from ongoing studies in Australia.

Sanofi is making a bigger bet on next-generation immune cell redirection in autoimmune disease. The latest signal is its deal with Kali Therapeutics for KT501, a tri-specific T-cell engager designed ...

Sanofi has licensed rights to Kali's trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.

Sanofi partners with Kali Therapeutics in TCE deal worth $180M upfront plus $1B in milestones, centered on KT501 for rheumatoid arthritis. CEO Weihao Xu leads development.

Kali Therapeutics has secured an exclusive license agreement with Sanofi to advance its innovative T-cell engager, KT501, targeting autoimmune diseases. This collaboration aims to enhance treatment options.

Kali Therapeutics has announced the successful dosing of the first patient in its Phase 1a trial for KT501, a promising treatment for rheumatoid arthritis.

SAN MATEO, Calif., March 18, 2026 /PRNewswire/ -- Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting therapies, today announced that dosing is underway for the first cohort of patients in its Phase 1a clinical trial evaluating KT501....